Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients

Arthritis Rheum. 1994 Dec;37(12):1770-3. doi: 10.1002/art.1780371210.

Abstract

Objective: To determine methotrexate (MTX) concentrations in the synovial membrane (SM) and cortical and trabecular bone of rheumatoid arthritis (RA) patients.

Methods: Ten RA patients (9 women, 1 man; mean +/- SD age 49.2 +/- 10.6, mean disease duration 13.2 +/- 9.9 years) undergoing surgical procedures for rheumatoid articular lesions participated in this study. Mean +/- SD MTX treatment duration was 26.4 +/- 21.3 months. The day preceding surgery, 10 mg of MTX was administered intramuscularly. During surgery, a mean +/- SD of 19.7 +/- 2.6 hours after MTX administration, SM, bone fragments, and blood were collected simultaneously. MTX was assayed by fluorescence polarization immunoassay in plasma and tissues.

Results: The mean +/- SD plasma concentration was 0.0252 +/- 0.01 nmoles/ml at the time of tissue sampling. The mean MTX concentration in SM was 0.285 +/- 0.159 nmoles/gm. The mean MTX concentrations in trabecular and cortical bone were 0.292 +/- 0.164 and 0.286 +/- 0.126 nmoles/gm, respectively.

Conclusion: After intramuscular administration, high MTX concentrations are found in SM and cortical and trabecular bone of RA patients.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Arthritis, Rheumatoid / metabolism*
  • Arthritis, Rheumatoid / surgery
  • Bone and Bones / chemistry*
  • Female
  • Humans
  • Injections, Intramuscular
  • Male
  • Methotrexate / administration & dosage
  • Methotrexate / analysis*
  • Middle Aged
  • Synovial Membrane / chemistry*

Substances

  • Methotrexate